Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 4/2018

01-08-2018 | ORIGINAL ARTICLE

Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia

Authors: Tobias Schupp, Michael Behnes, Christel Weiß, Christoph Nienaber, Siegfried Lang, Linda Reiser, Armin Bollow, Gabriel Taton, Thomas Reichelt, Dominik Ellguth, Niko Engelke, Uzair Ansari, Ibrahim El-Battrawy, Thomas Bertsch, Muharrem Akin, Kambis Mashayekhi, Martin Borggrefe, Ibrahim Akin

Published in: Cardiovascular Drugs and Therapy | Issue 4/2018

Login to get access

Abstract

Objective

The study sought to assess the impact of treatment with beta-blocker (BB) or ACE inhibitor/angiotensin receptor blocker (ACEi/ARB) on secondary survival in patients presenting with ventricular tachyarrhythmia.

Background

Data regarding outcome of patients presenting with ventricular tachyarrhythmia treated with BB and ACEi/ARB is limited.

Methods

A large retrospective registry was used including consecutive patients presenting with ventricular tachycardia and fibrillation from 2002 to 2016 on admission. Applying propensity-score matching for harmonization, the impact of “BB” and “ACEi/ARB” was comparatively evaluated. The primary prognostic outcome was long-term all-cause death at 3 years.

Results

A total of 972 matched patients were included. Both patients with BB (long-term mortality rate 18 versus 27%; log rank p = 0.041; HR = 0.661; 95% CI = 0.443–0.986; p = 0.043) and with ACEi/ARB (long-term mortality rate 13 versus 23%; log rank p = 0.004; HR = 0.544; 95% CI = 0.359–0.824; p = 0.004) revealed better secondary survival compared to patients without after presenting with ventricular tachyarrhythmia on admission. The prognostic benefit of BB was comparable to ACEi/ARB (long-term mortality rate 21 versus 26%; log rank p = 0.539).

Conclusion

BB and ACEi/ARB were associated with improved secondary survival in patients surviving ventricular tachyarrhythmia on admission.

Trial Registration

ClinicalTrials.gov identifier: NCT02982473
Appendix
Available only for authorised users
Literature
1.
go back to reference Priori, S.G., et al., 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal, 2015. 36(41): p. 2793–2867. Priori, S.G., et al., 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal, 2015. 36(41): p. 2793–2867.
2.
go back to reference Refaat MM, Hotait M, London B. Genetics of sudden cardiac death. Curr Cardiol Rep. 2015;17(7):53.CrossRef Refaat MM, Hotait M, London B. Genetics of sudden cardiac death. Curr Cardiol Rep. 2015;17(7):53.CrossRef
3.
go back to reference Arshad A, Mandava A, Kamath G, Musat D. Sudden cardiac death and the role of medical therapy. Prog Cardiovasc Dis. 2008;50(6):420–38.CrossRefPubMed Arshad A, Mandava A, Kamath G, Musat D. Sudden cardiac death and the role of medical therapy. Prog Cardiovasc Dis. 2008;50(6):420–38.CrossRefPubMed
4.
go back to reference Katritsis DG, Gersh BJ, Camm AJ. A clinical perspective on sudden cardiac death. Arrhythmia Electrophysiol Rev. 2016;5(3):177–82.CrossRef Katritsis DG, Gersh BJ, Camm AJ. A clinical perspective on sudden cardiac death. Arrhythmia Electrophysiol Rev. 2016;5(3):177–82.CrossRef
6.
7.
go back to reference Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol. 2007;32(9):501–46.CrossRefPubMed Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol. 2007;32(9):501–46.CrossRefPubMed
8.
go back to reference Kamath GS, Mittal S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Prog Cardiovasc Dis. 2008;50(6):439–48.CrossRefPubMed Kamath GS, Mittal S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Prog Cardiovasc Dis. 2008;50(6):439–48.CrossRefPubMed
9.
go back to reference Landray MJ. Sudden death: ACE inhibitors and beta-blockers. Vol 95 Suppl 1. 2000. I37–40. Landray MJ. Sudden death: ACE inhibitors and beta-blockers. Vol 95 Suppl 1. 2000. I37–40.
10.
go back to reference Cohen-Solal A, Jacobson AF, Piña IL. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Failure. 2017;4:499–506.CrossRefPubMedPubMedCentral Cohen-Solal A, Jacobson AF, Piña IL. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Failure. 2017;4:499–506.CrossRefPubMedPubMedCentral
11.
go back to reference Weeks PA, Sieg A, Gass JA, Rajapreyar I. The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. Heart Fail Rev. 2016;21(4):415–31.CrossRefPubMed Weeks PA, Sieg A, Gass JA, Rajapreyar I. The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. Heart Fail Rev. 2016;21(4):415–31.CrossRefPubMed
12.
go back to reference Boriani G, Diemberger I, Valzania C, Biffi M, Martignani C, Raschi E, et al. Role of drugs and devices in patients at risk of sudden cardiac death. Fundam Clin Pharmacol. 2010;24(5):575–94.CrossRefPubMed Boriani G, Diemberger I, Valzania C, Biffi M, Martignani C, Raschi E, et al. Role of drugs and devices in patients at risk of sudden cardiac death. Fundam Clin Pharmacol. 2010;24(5):575–94.CrossRefPubMed
13.
go back to reference Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Circulation. 1995;92(10):3132–7.CrossRefPubMed Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Circulation. 1995;92(10):3132–7.CrossRefPubMed
14.
go back to reference Heart Outcomes Prevention Evaluation Study, I., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–53.CrossRef Heart Outcomes Prevention Evaluation Study, I., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–53.CrossRef
15.
go back to reference Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter-defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of >35,000 patients. Int J Cardiol. 2014;173(2):197–203.CrossRefPubMed Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter-defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of >35,000 patients. Int J Cardiol. 2014;173(2):197–203.CrossRefPubMed
16.
go back to reference Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66(13):1431–41.CrossRefPubMedPubMedCentral Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66(13):1431–41.CrossRefPubMedPubMedCentral
17.
go back to reference Investigators C-I. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.CrossRef Investigators C-I. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.CrossRef
18.
go back to reference Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol. 2003;41(9):1529–38.CrossRefPubMed Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol. 2003;41(9):1529–38.CrossRefPubMed
19.
go back to reference Priori SG, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J, 2015 36(41): p. 2793–867. Priori SG, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J, 2015 36(41): p. 2793–867.
20.
go back to reference Ponikowski P, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2016. 37(27): p. 2129–200. Ponikowski P, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2016. 37(27): p. 2129–200.
21.
go back to reference Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.CrossRefPubMedPubMedCentral Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.CrossRefPubMedPubMedCentral
22.
23.
go back to reference Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 2003;14(s9):S87–95.CrossRefPubMed Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 2003;14(s9):S87–95.CrossRefPubMed
24.
go back to reference Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med, 1981; 304(14): p. 801–7. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med, 1981; 304(14): p. 801–7.
25.
go back to reference Olsson G, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13(1):28–32.CrossRefPubMed Olsson G, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13(1):28–32.CrossRefPubMed
26.
go back to reference Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol. 1986;7(1):1–8.CrossRefPubMed Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol. 1986;7(1):1–8.CrossRefPubMed
27.
go back to reference Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE Investigators. Circulation. 1994;90(4):1731–8.CrossRefPubMed Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE Investigators. Circulation. 1994;90(4):1731–8.CrossRefPubMed
28.
go back to reference Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet. 1997;349(9064):1493–7.CrossRefPubMed Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet. 1997;349(9064):1493–7.CrossRefPubMed
29.
go back to reference Torp-Pedersen C, Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction. Lancet. 1999;354(9172):9–12.CrossRefPubMed Torp-Pedersen C, Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction. Lancet. 1999;354(9172):9–12.CrossRefPubMed
30.
go back to reference Ponikowski P, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2016; 37(27): p. 2129–2200. Ponikowski P, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2016; 37(27): p. 2129–2200.
31.
go back to reference Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355(9215):1575–81.CrossRefPubMed Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355(9215):1575–81.CrossRefPubMed
32.
go back to reference Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet, 1999. 353(9169): p. 2001–2007. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet, 1999. 353(9169): p. 2001–2007.
33.
go back to reference Kochs M, Eggeling T, Hombach V. Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death. Eur Heart J. 1993;14(suppl_E):107–19.CrossRefPubMed Kochs M, Eggeling T, Hombach V. Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death. Eur Heart J. 1993;14(suppl_E):107–19.CrossRefPubMed
34.
go back to reference Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Card Imaging. 82(4):9I–19I. Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Card Imaging. 82(4):9I–19I.
35.
go back to reference Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 1991;68(10):1025–31.CrossRefPubMed Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 1991;68(10):1025–31.CrossRefPubMed
36.
go back to reference Brodsky MA, Allen BJ, Bessen M, Luckett CR, Siddiqi R, Henry WL. Beta-blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction. Am Heart J. 1988;115(4):799–808.CrossRefPubMed Brodsky MA, Allen BJ, Bessen M, Luckett CR, Siddiqi R, Henry WL. Beta-blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction. Am Heart J. 1988;115(4):799–808.CrossRefPubMed
37.
go back to reference Brodsky MA, Allen BJ, Luckett CR, Capparelli EV, Wolff LJ, Henry WL. Antiarrhythmic efficacy of solitary beta-adrenergic blockade for patients with sustained ventricular tachyarrhythmias. Am Heart J. 1989;118(2):272–80.CrossRefPubMed Brodsky MA, Allen BJ, Luckett CR, Capparelli EV, Wolff LJ, Henry WL. Antiarrhythmic efficacy of solitary beta-adrenergic blockade for patients with sustained ventricular tachyarrhythmias. Am Heart J. 1989;118(2):272–80.CrossRefPubMed
38.
go back to reference AlJaroudi WA, et al. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol. 2015;115(7):924–31.CrossRefPubMedPubMedCentral AlJaroudi WA, et al. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol. 2015;115(7):924–31.CrossRefPubMedPubMedCentral
39.
go back to reference James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMed James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMed
40.
go back to reference Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.CrossRefPubMed Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.CrossRefPubMed
41.
go back to reference Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327(10):678–84.CrossRefPubMed Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327(10):678–84.CrossRefPubMed
Metadata
Title
Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia
Authors
Tobias Schupp
Michael Behnes
Christel Weiß
Christoph Nienaber
Siegfried Lang
Linda Reiser
Armin Bollow
Gabriel Taton
Thomas Reichelt
Dominik Ellguth
Niko Engelke
Uzair Ansari
Ibrahim El-Battrawy
Thomas Bertsch
Muharrem Akin
Kambis Mashayekhi
Martin Borggrefe
Ibrahim Akin
Publication date
01-08-2018
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 4/2018
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-018-6812-z

Other articles of this Issue 4/2018

Cardiovascular Drugs and Therapy 4/2018 Go to the issue